Articles

Videos

Podcasts

Clinical Role

The durvalumab plus chemotherapy arm demonstrated a statistically significant improvement in PFS versus chemotherapy in the previous analysis, but the OS trend observed in this analysis did not achieve statistical significance.

Durvalumab, Tremelimumab With Chemotherapy Shows Overall Survival Benefit in Non-Small Cell Lung Cancer

As breast cancer becomes an increasingly treatable disease, clinicians should provide personalized follow-up care to address varying burdens of symptoms up to 5 years after diagnosis.

Individualized Follow-Up Care Can Address Various Health Burdens in Breast Cancer Survivors

The KEYNOTE-522 trial met its dual primary endpoints of pathologic complete response and event-free survival, showing a statistically significant and clinically meaningful improvement in EFS compared to neoadjuvant chemotherapy alone.

Clinical Trial of Pembrolizumab Shows Improved Event-Free Survival in High-Risk, Early-Stage Triple-Negative Breast Cancer

The implementation of multi-gene panel testing may be a necessary part of the standard of care for all colorectal cancer patients.

Multi-Gene Testing in Colorectal Cancer Patients Could Detect More Hereditary Cancer Syndromes

Loneliness and social isolation have been particularly significant problems for patients with cancer during the COVID-19 pandemic, likely due to isolation and social distancing, according to a study published in Cancer. 

Patients With Cancer Facing Higher Rates of Loneliness, Depression During COVID-19 Pandemic

Data presented at the 2021 ESMO Breast Cancer Virtual Congress showed 29% of recurrent breast cancer biopsies showed conversion either from, or to, HER2-low expression.

Study: Breast Tumors Evolving to HER2-Low May Provide Broader Therapeutic Options

In June 2020, the FDA granted a fast track designation to fruquintinib for patients with mCRC previously treated with other therapies.

Managing Refractory Metastatic Colorectal Cancer With Fruquintinib

In an interview with Pharmacy Times®, Melissa Santibañez, PharmD, BCCCP, assistant professor at Nova Southeastern University College of Pharmacy, Fort Lauderdale, Florida; and critical care clinical pharmacist at Memorial Regional Hospital, Hollywood, Florida, discusses the value of a pharmacist on a patient care team. 

Value of a Pharmacist on a Care Team

Tivozanib was the first therapy approved by the FDA for adult patients with relapsed or refractory advanced renal cell carcinoma following 2 or more prior systemic therapies.

Pharmacist Medication Insights: Tivozanib for Renal Cell Carcinoma

These findings also suggest that the efficacy of radiotherapy can be improved with drugs that block the PDGFRb protein. 

Oncology